Effect of a Biweekly Dosing Schedule on Severe Neutropenia Induced by Trifluridine/Tipiracil in Colorectal Cancer
The biweekly schedule of TAS-102 with/without bevacizumab was associated with a significantly lower incidence of grade ≥3 neutropenia than the standard schedule. This schedule may help patients - including those with impaired renal function - adhere to planned treatment regimens.
Authors
- Hiroshi Matsuoka (ORCID: https://orcid.org/0000-0002-7837-565X)
- Hideki Orito
- Koichi Suda (ORCID: https://orcid.org/0000-0002-0423-1565)
- Akio Horiguchi (ORCID: https://orcid.org/0000-0002-7678-6375)
- Zenichi Morise (ORCID: https://orcid.org/0000-0001-6382-6502)
- Hidetoshi Katsuno (ORCID: https://orcid.org/0000-0002-7054-7808)
- Tomohiro Mizuno (ORCID: https://orcid.org/0000-0001-8203-392X)
- Shigeki Yamada (ORCID: https://orcid.org/0000-0002-3891-1323)
- Takahiro Hayashi (ORCID: https://orcid.org/0000-0002-9686-6903)
- Yosuke Ando (ORCID: https://orcid.org/0000-0001-8166-8165)
Institutions
- Fujita Health University (JP)
- Kinjo Gakuin University (JP)
- Fujita Health University Hospital (JP)
- Fujita Health University Okazaki Medical Center
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-05-27
- DOI
- https://doi.org/10.21873/anticanres.17630
- Primary Topic
- Neutropenia and Cancer Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00